ReviewFrontiers in oncology2025
The impact of METTL3 on bladder cancer through m
Review in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- ANKRD1 expression and functional mechanism in stomach adenocarcinoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Article
- The Central Role of m6A as Epigenetic Regulator in Metabolic Disorders of Therapeutic Potential and Clinical Implications.Molecular neurobiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer (BCa) is one of the most prevalent malignant tumors globally, particularly among men. According to data from the Global Cancer Research Agency, the annual incidence of BCa continues to rise, and its clinical features are complex, involving various molecular mechanisms and pathophysiological processes. Although existing treatments such as surgery, chemotherapy, and immunotherapy have improved patient prognosis to some extent, many individuals remain at risk for recurrence and metastasis. Therefore, there is an urgent need to explore new biomarkers and therapeutic targets to enhance the diagnostic and therapeutic efficacy of BCa. In recent years, RNA methylation, as an important post-transcriptional modification, has gradually attracted the attention of researchers. Among the methyltransferases, methyltransferase-like 3 (METTL3) is considered a key regulator, which is mainly responsible for the N6-methyladenosine (m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.